Breaks Categories: News

WednesdayJan 06, 2021 2:08 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Releases Report on Patent Filings, Therapeutics Program Development

Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, has provided an update on its patent filings. The company has eight filings, all tied to Cybin’s novel therapeutics, delivery mechanisms and treatment regiments. The patent updates noted that Cybin has patent applications for the following: a provisional patent application for an oral film delivery mechanism covering all psychedelic molecules delivered through oral films; a delivery technology covering various chemically synthesized psychedelic molecules; multiple patent applications for deuterated psychedelic molecules and analogues; and a patent application for platforms that create supportive treatment regimens. The company also announced that…

Continue Reading

WednesdayDec 30, 2020 10:33 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) Commences Study to Further Knowledge in Psilocybin, Associated Delivery Mechanisms

Pure Extracts Technologies (CSE: PULL) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushrooms sector, today announced that it is commencing a study on the formulation and manufacturing of psilocybin-based active treatments for oral tablets, capsules and a nasal gel that will be used as an investigational product. According to the update, the study with be conducted at the Toronto Institute of Pharmaceutical Technology (“TIPT”) by Dr. Alexander MacGregor, a key scientific advisor to Pure Extracts. The study will focus on formulating, manufacturing and clinical bioavailability testing of rapid onset psilocybin dosage forms…

Continue Reading

WednesdayDec 30, 2020 10:25 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Announces Q1 Results for Clarmin Explorations

Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, on Tuesday announced the unaudited financial results of Clarmin Explorations Inc. (now Cybin Inc.) for the three month period ended Oct. 31, 2020. According to the update, a copy of the consolidated financial statements prepared in accordance with International Financial Reporting Standards, as well as the corresponding management’s discussion and analysis for the three months ended Oct. 31, 2020, can be found under Cybin’s profile at www.SEDAR.com. To view the full press release, visit https://ibn.fm/br5Uw About Cybin Inc. Cybin is a life sciences company advancing psychedelic pharmaceutical treatments…

Continue Reading

WednesdayDec 16, 2020 11:04 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) Begins Facility Build-Out, Prepares to Apply for Dealer’s Licence

Pure Extracts Technologies (CSE: PULL), a plant-based extraction company, has begun build-out work on the fourth unit in is extraction facility; in addition, the company is preparing to submit application to Health Canada requesting a dealer's licence under the Controlled Drugs and Substances Act (“CDSA”), the government entity that provides the framework for legal access to controlled substances, including the control and regulation of production, distribution and sale of psilocybin. Based on guidelines, a company must have a Health Canada-issued licence in order to conduct business with controlled substances. A license could allow Pure Extracts to procure controlled substances; research…

Continue Reading

TuesdayDec 15, 2020 10:43 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) Notes Appreciation for Health Canada Milestone Special Access Programme

Pure Extracts Technologies (CSE: PULL), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector, has voiced its support and appreciation for Health Canada’s recently announced Special Access Programme (“SAP”) for psilocybin-assisted psychotherapy inclusion. The government entity recently announced its intent to revise the SAP and other related regulations to allow limited uses of psilocybin-assisted psychotherapeutic treatments. The SAP revision may open the door to new medical applications in the mental health space and support the progress of advanced research initiatives, including ongoing clinical trials evaluating psilocybin-assisted psychotherapy. The proposed SAP update may also positively…

Continue Reading

MondayDec 14, 2020 10:56 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Joins Forces with Adelia Therapeutics to Potentially Address Treatment Gaps Beyond Major Depressive Disorder

Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, today announced the close of its acquisition of 100% of the shares in Adelia Therapeutics Inc. for up to CA$20,161,575 (approximately US$15.75 million). “We are thrilled to join forces with Adelia. We see this acquisition as potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder,” said Cybin CEO Doug Drysdale. “Adelia’s focuses on novel delivery methods and innovative therapies may contribute to our goal of therapies with faster onset of action, smoother pharmacokinetic profiles, shorter treatment periods, and reduced side…

Continue Reading

ThursdayDec 10, 2020 3:09 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Announces Agreement to Acquire Adelia Therapeutics

Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, recently announced its entry into a definitive agreement to acquire 100% of the shares in Adelia Therapeutics Inc. for up to CA$20,161,575 (approximately US$15.75 million) in an all-stock transaction. The transaction is subject to the satisfaction or waiver of customary conditions, including receipt of all applicable regulatory and NEO Exchange Inc. approvals. “We are thrilled to join forces with Adelia, as we see this transaction as potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder. Adelia’s focus on creating novel…

Continue Reading

ThursdayDec 10, 2020 10:09 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) Lays Groundwork for Move into World of Psychedelics

Pure Extracts Technologies (CSE: PULL) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector, today announced its engagement of a globally recognized operations, compliance and regulatory consulting firm to advise on the company’s application to Health Canada for a Dealers Licence under the Controlled Drugs and Substances Act (“CDSA”). “Having the support of one of Canada’s premiere consulting companies with subject matter proficiency in cannabis and other regulated consumer product industries assures that we will submit a fully-compliant Dealers Licence application to Health Canada in the shortest time possible,” said Pure Extracts…

Continue Reading

WednesdayDec 09, 2020 10:03 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) Announces LOI with Owner of PURICA(TM) Brand of Wellness Product

Pure Extracts Technologies (CSE: PULL), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector, recently signed a letter of intent with the Nutraceutical Medicine Company Inc. (“PURICA”). PURICA owns and distributes the PURICA product line of full-spectrum, mushroom-derived wellness products. Pure Extracts anticipates the PURICA brand will support PULL’s expansion into the functional mushroom sector. For the past two decades, PURICA has offered natural and whole food products that are backed by science. The company’s Immune 7 formulation has been the Alive Award gold winner for the best immunity product in Canada two years in a…

Continue Reading

WednesdayDec 02, 2020 10:22 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) Announces Working Collaboration with Leading Pharmaceutical Science Inventor

Pure Extracts Technologies (CSE: PULL), a plant-based extraction company specializing in cannabis, hemp and mushroom products, has announced its partnership with Dr. Alexander MacGregor, a key scientific advisor the company. A renowned expert in pharmaceutical technology and novel drug-delivery systems, MacGregor is a dean of faculty and a distinguished professor of biopharmaceutics and current president of the Toronto Institute of Pharmaceutical Technology (“TIPT “), the premier post-graduate institute of pharmaceutical sciences, technology and research in North America. He is also the CEO of TIPT’s parent company, Transpharm Canada Inc., which conducts cannabis testing and clinical trials. MacGregor will be working with…

Continue Reading